Oculus Innovative Sciences has received FDA clearance to market Microcyn Skin and Wound Gel as both a prescription and over-the-counter formulation. The prescription product is indicated for the management of exuding wounds (eg, leg, pressure, and diabetic ulcers) and for the management of mechanically or surgically debrided wounds.

Microcyn Skin and Wound Gel is expected to be available in June 2009.

For more information call (678) 213-0649 or visit www.oculusis.com.